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Summary.-A mortality analysis has been carried out on a cohort of patients given
Fowler's solution (potassium arsenite) for periods ranging from 2 weeks to 12 years
between 1945 and 1969. An excess of fatal and non-fatal skin cancer was apparent,
but there was no overall excess mortality from cancer. Further analyses by site of
cancer, dose level, and time from first exposure are also presented. A subset of
patients were examined in 1969-70 for the presence of arsenical keratoses, hyper-
pigmentation and skin cancer. About half the patients had one or more of these
signs. Although the cancer mortality of this entire subgroup was similar to the
expected value, all the cancer deaths occurred in patients with prior signs of arseni-
cism. These data suggest that while any excess of internal malignancy due to the
use of Fowler's solution is small or non-existent, there may be a susceptible subgroup
which can be identified from dermatological manifestations.
IT HAS BEEN clearly established that
skin cancer is one of the sequelae of
exposure to arsenic, whether heavy en-
vironmental (Bergoglis, 1964; Yeh, 1973),
industrial (Neubauer, 1947; Roth, 1956;
Rockstoh, 1959) or medicinal (Hutchinson,
1888; Neubauer, 1947; Evans, 1976), and
that lung cancer can be produced at high
levels of airborne inorganic arsenicals, as
in pesticide workers (Ott et al., 1974;
Mabuchi et al., 1980), sheep-dip manu-
facturers (Hill & Fanning, 1948) and cop-
per smelters (Lee & Fraumeni, 1969;
Tokudome & Kuratsune, 1976; Axelson
et al., 1978). The position about other
cancers is less clear, and opinion ranges
from the belief that arsenic has a carcino-
genic effect on a wide range of internal
organs (Dobson & Pinto, 1966; Regelson
et al., 1968; Ott et al., 1974) to its having
a protective effect (Frost, 1.977). Case
reports have suggested that prolonged
use of Fowler's solution (potassium arsen-
ite, KAsO2) may be associated with
cancers at internal sites, including lung
(Robson & Jelliffe, 1963), nasopharynx
(Atkinson, 1969; Prystowsky et al., 1978),
liver (especially haemangiosarcoma) (Re-
gelson et al., 1968; Lander et al., 1975;
Cowlishaw et al., 1979), colon (Sommers &
McManus, 1953), lymphatic tissue (Som-
mers & McManus, 1953) and bladder
(Atkinson, 1969). However, in the one
large cohort study reported by Reymann
et al. (1978), no excess of internal cancers
was found. On the other hand, in that
report, as in some others (Sommers &
McManus, 1953; Mabuchi et al., 1980), a
relationship between the signs of arsenic
toxicity (keratoses and hyperpigmenta-
tion) and internal malignancies has been
suggested, but none of these studies have
had a reference set of expected values
from which comparisons andl inferences
could be drawn. The two case-control
studies (Dobson et al., 1965; Bean et al.,
1.968) which investigated the presence of
keratoses at the time of diagnosis of
cancer have reportedl contradictory
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PATIENTS AND METHODS
A mortality analysis has been carried out
on a cohort of 478 patients given Fowler's
solution for lengths of time ranging from
2 weeks to 12 years during the period 1945-
1969 in rural south Lancashire. It was known
that patients in a local dermatology out-
patients clinic had been treated with Fowler's
solution during this period, and the cohort
was assembled by searching local hospital
records for evidence of prescriptions for this
preparation. A total of 479 case-sheets were
extracted. All but 13 of these patients had
been treated for skin complaints, the excep-
tions being treated for a miscellany of
conditions including malaria, anaemia, epi-
lepsy, and anxiety. The patients were not
selected because of the development of
arsenic-induced skin lesions. Follow-up to
1 January 1980 has been accomplished by
"flagging" patients in the National Health
Service Central Registry located in Southport.
Patients were censored ontheir 85th birthday,
because of the unreliability of the expected
values in the open-ended group beyond that
age. Thus deaths (18 in all) and person-years
at risk after age 85 were ignored. In addition,
one person whose risk period began at the
age of 88 was completely excluded, leaving a
total of 478 eligible patients. Further
ainalyses with censoring at age 101 gave
sinmilar results.
Within this defined risk period, 139 deaths
have occurred, 265 patients were known to be
alive and at risk, 29 had passed 85 years of
age, 19 have emigrated, and 26 were not
traced. Patients who emigrated were censored
at their date of emigration. Many of the
untraced patients were known to have been
alive recently, and it is likely that most were
alive on 1.1.80, as has been assumed in the
analysis below. The assumption leads to
expected values which are probably 1-20/
too large, and certainly no more than 500 too
large. Expected values (E) are based on age-,
sex-, and calendar-year-adjusted rates for
England and Wales. As the standardized
mortality ratios (SMR) for all causes and all
neoplasms for this part of Lancashire are 101
and 93 respectively, we have chosen not to
adjust the expected values for them, though
this suggests that the expected numbers we
have used for cancers may be a few per cent
too large. Occupational information was not
available for all patients. However most of
the given occupations would be grouped in
social classes If and 111. There was no
indication that the cohort differed markedly
in social classfromthatofthelocalpopulation.
In 1969, one of us (S.E.) wrote to all
members of the cohort who had been traced
and were known to be alive, with the intention
of examining them and conducting further
studies. By the end of 1970, a subset consist-
ing of 142 patients had been seen, and the
presence ofarsenical keratoses, hyperpigmen-
tation, and skin cancer was recorded. At that
time no signs of internal malignancy were
clinically apparent. Further analyses of this
subgroup were carried out for a risk period
which began on the date they were examined.
The remainder of the cohort, and the risk
period for this subset before they had been
examined, were combined to form a compari-
son group.
Significance levels and confidence intervals
for the ratio O/E are based on Poisson
statistics. Because the dosage levels are very
skewed (a few patients have massive doses),
ordinal scores have been used for tests of
trend, and significance levels have been
determined from a normal approximation. In
computing expected values for various dose
levels, we have attributed the entire risk
period to the category associated with the
total dose received, as opposed to the more
accurate method of changing group member-
ship as the levels accumulate. This will tend
to make the expected values slightly too
small in the lower dosage categories and
slightly too large at the higher doses. How-
ever, most patients were on treatment for
less than a year, so this correction can be
safely neglected. Two-sided P values have
been used throughout.
RESULTS
The mean age of patients at time of
treatment was 40 0 years and 213 (45%)
were male. Risk ratios were similar for
males and females, and only combined
data are presented below. Dose levels are
given for elemental arsenic, and were
computed by multiplying prescribed daily
dose by the duration of treatment. A
histogram for total dose levels of arsenic
is shown in the Figure. The median dose
was 448 mg, but the mean dose was
1891 mg because a few patients received
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FIG. Distribution of patients by cumulative dose of arsenic.
very large doses. The mean duration of
treatment was 8-92 months, and most
patients consumed arsenic at the near-
average rate of - 250 mg/mo. The mean
follow-up time was 20-3 years.
Table I shows observed and expected
values for various causes of death. Deaths
from all causes are lower than the number
expected from the rates for England and
Wales (P =0.07) but deaths due to neo-
plasms are similar to their expected value.
Furthermore, a proportional mortality
analysis did not show a significant excess
of cancer deaths (P = 049, details not
shown). At no site was there a statistically
significant excess, though the 3 bladder
cancers are in excess of the expected
number of 1P19. An analysis by dose level
is shown in Table II for all neoplasms,
digestive cancers and respiratory cancers.
No clear trend is apparent, though the
risk ratio is low in all 3 groups for patients
receiving <500 mg of arsenic, and the
mortality from all neoplasms at this dose
level is significantly low (P=0.05). A
breakdown by dose and time from first
exposure for all neoplasms is shown in
Table III. Again there is no firm indication
of an excess of cancer following higher
doses or longer follow-up periods. A
TABLE I.- Causes of death in 478 patients treated with Fowler's solution
Cause (ICD code, 8tlh revision)
All causes
All neoplasms (140-239)
Ca digestive organs (150-157, 197 - 7, 197 8)
Ca iespiratory (160-163, 140-141, 143-149)
Ca skin (172 -0-173 -4, 173 - 6-173 -9)
Ca bladder (188, 189 - 9)
Ca liver and gall bladder (155-156, 197 7, 197 8)
Haematopoietic and lymphatic neoplasms (200-208)
All circulatory disease (390-443, 445-458)
Ischaemic heart disease (410-414)
Cerebrovascular disease (430-438)
Observed Expected 90% confidence
deaths (0) deaths (E) limits for O/E
139
34
1:3
:11
1
1 1
7:3
:37
16
161 - 18
35- 75
12-37
9.99
0-28
1.19
0-75
1 -84
83 - 38
40-47
22-40
0-75-0-99
0 - 70-1 - 27
0-62-1 -67
0 -62-1 82
0- 18-16 - 9
0-69-6-51
0-07-6-32
0-03-2 -58
0-71-1 -06
0-68-1 -20
0-45-1-08
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TABLE II.-Observed and expected numbers ofdeathsfor specific groups of cancers by dose
level of arsenic
Site
(ICD code, 8th revision)
All neoplasms
(140-239)
x2 for trend =0 64
Ca digestive organs
(150-157, 197-7, 197-8)
x2 for trend = 1-00
Ca respiratory organs
(160-163, 140-141, 143-149)
x2 for trend = 0 - 75
All causes
x2 for trend =0 99
Cumulative
dose level
(mg)
< 500
500-999
1000-1999
> 2000
< 500
500-999
1000-1999
> 2000
< 500
500-999
1000-1999
> 2000
< 500
500-999
1000-1999
> 2000
Observed
No. of deaths
patients (0)
242
99
59
78
242
99
59
78
242
99
59
78
242
99
59
78
10
9
7
8
3
4
3
3
4
2
2
3
63
32
18
26
TABLE III.-Observed (0) and expected (E) cancers by
treatment
dose and time from first known
Dose (mg)
, K \~~~~~~~~~~~~~~
Time < 500
(years) 0 E O/E
<5 0 2-99 0.00
5-9 3 3-37 0-89
10+19 4 7-14 0-56
500-999 1000-1999
\( -
1
0 E O/E 0 E O/E O
2 1-45 1-38 0 1-05 0 00 0
3 1-25 2-40 1 1-04 0-96 4
4 2-21 1-81 4 1-75 2-29 0
> 2000
E O/E
0 95 0 00
1-01 3.95
1-86 0.00
>20 3 4-84 0-62 0 1-87 0 00 2 0 74 2-69 4 2-33 1-72
x2 for trend 2 -59 0 07 3-46 0-64
All levels
O E O/E
2 6-45 0-31
11 6-67 1-65
12 12-90 0 93
9 9 78 0 92
0-01
significant trend (X2=6X62, P=0.01) is
found for dose in the period 5-9 years
from first exposure. However, as this is
not reflected in the other intervals, and as
carcinogenesis requires a longer induction
period than this for most other carcino-
gens, this trend is almost certainly due to
chance. Further analysis, by calendar
year at first exposure or duration of
treatment, failed to reveal any further
trends.
The 142 patients who were examined
for skin manifestations of arsenicism
suggested an interesting potential dicho-
tomy. As a group their overall mortality
(O/E =29/30X38) and cancer mortality
(O/E= 7/6.90) was not remarkable, and
was consistent with the remainder of the
cohort (Table IV). Within this group,
45% had keratoses, 14% had hyper-
pigmentation, and 11% were found to
have skin cancer. Some patients showed
2 or all 3 signs of arsenicism, and alto-
gether 69 (49%) showed at least one of
these signs. The appearance of signs was
dose and age related. Patients with signs
had higher median doses (672 mg) than
those without any signs (448 mg) and this
was highly significant when assessed by
the Wilcoxon rank-sum test (P=0.001).
Furthermore 40% of patients with signs
had cumulative doses above 1000 mg,
which applied to only 22% of patients
without arsenical signs. On average,
patients with signs were 7 years older and
had received theirfirst exposure 6 calendar
years earlier. Within the group with
exposures > 1000 mg, those with signs
Expected
deaths
(E)
18-24
6-78
4-58
6-15
6-41
2-30
1 -58
2 -08
5*03
1 87
1-39
1 70
83 39
29 93
21*15
26 72
O/E
0.55
1-33
1 53
1 30
0 47
1*74
1.90
1-44
0-80
1-07
1-44
1 -76
0-76
1-07
0-85
0 97
x2 for
trend
2-33
6-62
0 00
0 43
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TABLE IV.-Mortality from all causes and all neoplasrms according to the presence of
arsenical keratoses, hyperpigmentation and/or skin cancer
Examined for- signs of +
arsenicism (dleaths -
after examination) T
Not examine(d for signs of
arsenicism (or deaths
before examination)
- o
69 20
73 9
14>2 29
336
(+'706 110
inan--years)
AllI causes
1605
14-33
:30-38
p
(2-si(de(l)
()038
( -19
()
7
E
3- 76
3 14
6-9(
130 84 -)-04 27 28 885
were again on average 7 years older an(d
had their first exposure 3 calendar years
earlier.
It is of interest that all 7 subsequient
deaths from internal malignancy occurred
within the group showing physical signs
of arsenicism. This excess over an ex-
pected 3-76 cancer deaths is not statis-
tically significant (P=0 17). The details
of these cases are listed in Table V. No
deaths from cancer occurred in the group
without physical signs (O/E = 0/3.14, P=
0.086).
Within the examined group, two other
individuals had cancer mentioned on the
death certificate, but not as the underlying
cause of death; both were clinically free
from cancer when examined. One had
cancer of the bladder and was a heavy
smoker; he had received 1800 mg of
arsenic over 2 months for eczema 15 vears
before death, and showed no signs of
arsenic exposure on examination 9 years
before death. The second was a woman
whose certified cause of death was a left
hemiplegia at age 77; she had a malignant
melanoma, and signs of arsenicism (in-
cluding a basal-cell carcinoma) had been
noted 7 years before death. On post-
mortem examination, bladder papillomas
were also found. She had received 173 mg
of arsenic more than 50 years previously
for p)yelitis.
DISCUSSION
These data provide at the most only a
weak indication that the ingestion of
Fowler's soltition over long periods leads
to anyr overall increase in mnortality fromii
cancer. The 90% coinfidence limits on the
risk ratio (0.70-1 27) and the mean
follow-up period (20 3 years) in conjunc-
tion with similar findings reporte(d by
Reymann et al. (1978) indicate that any
excess risk for all neoplasms must be
small. The mnost apparent feature was the
deficit of deaths from cancer and all
causes in patients receiving <500 mg of
arsenic. If this deficit, which was also
weak in the series of Reymann et al.
(1 978), canI be taken to reflect an incidence
of cancer among unexposed individuals
with this group of skin diseases, which is
below the national average, there may be
a significant excess of cancer due to
ingestioni of arsenic. H:owever, the lack of
a dose-response relation above 500 mg,
and the inability to find ani excess during
the period 10 or more years after first
known exposure, mnake this unlikely.
The number of cancers at a few sites
wvas in excess of expectation. A slight
excess oflung cancer was evident (Table I)
with a suggestion of a dose-response
relationship (Table II). Hlowever, both
these tendencies weice weak and far from
statistical significance. The one death
from malignant skin cancer (of the anus)
probably resulted from the use of arsenic.
A second death from multiple epithe-
liomas in a man at age 87 in whomn hyper-
pigmentation and skin cancer had been
nioted 9 years previously was not included
in the formal analysis because we have
specifically excluded observations on
people over 85 -years, but this death was
most p)robablv also due to arsenical
All nleoplasmIs
1-3
(2-si(le(l)
-17 0-0(8(5
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carcinogenicity. The slight excess of blad-
der cancer (3 observed, 1419 expected) is
less likely to be associated with arsenic.
These cases occurred in 2 women and a
man who had cumulative doses of 504,
963 and 3224 mg beginning 7, 8, and 6
years before death respectively. Unfor-
tunately we do not have detailed histories
from which other risk factors could be
assessed.
The one cancer death in the category of
"cancer ofthe liver, gall bladder, and bile
ducts" was due to a primary in the gall
bladder-a type of cancer that has not
been associated with arsenic. There were
no deaths from primary cancer ofthe liver.
The most notable positive finding was
the prior presence of keratoses among all
examined patients who later died from
cancer. Whilst the 7:0 split between the
groups with and without signs of arsen-
icism must be partly fortuitous, the sug-
gestion that the appearance of keratoses
or hyperpigmentation in cases exposed to
arsenic is associated with a higher risk of
internal malignancy is in keeping with
findings in other less controlled studies,
and merits further attention. A biological
basis for this phenomenon has been
suggested by Bettley & O'Shea (1975),
who found that pati6nts with arsenical
keratoses and superficial carcinomas had a
greater retention of a test dose of arsenic
than normal controls.
The lack of cancer in patients without
signs is more difficult to explain, and is
not supported by other evidence. It is
presumably due to chance, but the
possibility may be considered that patients
who fail to develop signs after exposure
to arsenic form a subgroup that is also less
susceptible to other carcinogens. It re-
mains possible that some ofthe contradic-
tory reports on the carcinogenicity of
arsenic can be explained by the variability
among individuals in their ability to
excrete ingested and inhaled doses of
arsenic.
We thank Sir Richard Doll for his helpful remarks
and Miss Carol Hermon for her expert technical
assistance.
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